Open AccessFavorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma
Author(s) -
Shingo Yano,
Takehiko Mori,
Yoshinobu Kanda,
Jun Kato,
Chiaki Nakaseko,
Shin Fujisawa,
Naoto Tomita,
Rika Sakai,
Katsuhiro Shono,
Takayuki Saitoh,
Nobuyuki Aotsuka,
Nobuhiko Kobayashi,
Takeshi Saito,
Satoshi Takahashi,
Heiwa Kanamori,
Shinichiro Okamoto
Publication year - 2015
Publication title -
bone marrow transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 127
eISSN - 1476-5365
pISSN - 0268-3369
DOI - 10.1038/bmt.2015.158
Subject(s) - medicine , refractory (planetary science) , transplantation , progressive disease , follicular lymphoma , surgery , lymphoma , gastroenterology , oncology , chemotherapy , physics , astrobiology
Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients-11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.